

May 25, 1983

Turan M. itil, M.D.
HZI Research
150 White Plains Road
Tarrytown, New York 10591

Dear Turan,

I have been puzzled by the evidence for the nootropic class of psychoactive substances. Using pharmaco-EEG methods, I studied a number of the peptides for which a nootropic status has been claimed. I was unable to elicit either an EEG profile or evidence of behavioral effects. I have also read the literature, and found the published data until 1981 thin and unpromising.

Lately, you have published an editorial supporting such a classification -- but the editorial lacked the evidence for the claim.

I recently came across the citation list for the special issue of Drug Development Research (2 (5), 1982) which has a number of titles which suggest that they might contain the evidence for such a classification. I requested a copy of the journal from our library, and we have no subscription; I requested an interlibrary loan, but as an unbound journal, it is not available. Hence this letter.

Do you have a copy of the issue ? Would you lend it to me for a few days ? Many thanks.

We began our first patient on Sertraline on Monday of this week. (We actually began two, but when I checked the inclusion criteria, one patient was 70 years of age, and Dr. Gholly rejected her.) I also sent a protocol for an EEG study for BHT 933 (azepexole) to Penny, and hope to examine it this Fall.

I trust Ellen and the children are well. We expect Jon next week, and Rachel said that she may fly up to visit with her brother as well. I cannot get to the NCDEU meetings this year, so will miss all the sunshine.

My best regards.

Sincerely yours,

Max Fink, M.D.